YCCI News

Everything you need to know about the FDA’s nicotine reduction plan.

Using a new technology they developed that delivers a specially designed cell-protective fluid to organs and tissues, the researchers restored blood circulation and other cellular functions in pigs a full hour after their deaths.

Yale researchers Akiko Iwasaki, PhD, and Harlan Krumholz, MD, are striving to solve the mysteries of long COVID, and to provide a compassionate voice for those feeling isolated and ignored by the medical community.

A new Yale study found that, among people suffering non-fatal heart attacks associated with hot weather, an outsize portion were taking beta-blockers or antiplatelet medication. The study doesn’t prove that these medications caused the heart attacks, nor that they make people more vulnerable to heart attack. Although it’s possible that they did increase the risk of heart attacks triggered by hot weather, it’s also possible that patients’ underlying heart disease explains both the prescriptions and the higher susceptibility to heart attack during hot weather.

Yale researchers have developed a new class of molecules that target some of the deadliest brain cancers while sparing healthy tissue. The discovery combines innovative synthetic chemistry and cutting-edge mechanistic studies in molecular biology, and offers a potentially powerful new approach to treating drug-resistant glioma tumors.

The experimental vaccines use engineered lipid nanoparticles to deliver mRNA to cells with “instructions” to create spike proteins from mutating variants, which the virus uses to attach to and infect cells.

Epigenetic clocks are powerful biomarkers based on DNA methylation that were developed to track aging in population studies, clinical trials, and personal health applications. Intended to measure biological age, they strongly predict age-related morbidity and mortality along with other aspects of health. Now, scientists from Yale School of Medicine, in collaboration with international research colleagues, have developed a new approach to make them substantially more reliable.

In a study published today in the journal JAMA Network Open, researchers at Yale Cancer Center assessed the acceptance of Medicaid insurance among patients diagnosed with common cancers.

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and when it might be necessary for individuals to get an additional booster shot. Now, a team of scientists led by faculty at the Yale School of Public Health and the University of North Carolina at Charlotte has an answer: strong protection following vaccination is short-lived.